Immuneering (IMRX) vs Keros Therapeutics (KROS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Keros Therapeutics (KROS) has outperformed Immuneering (IMRX) over the past year, losing 25.9% versus a loss of 36.9%. Over five years, KROS leads with a -69.4% price change compared with -84.2% for IMRX. Immuneering is the larger company by market cap ($254.9 million vs $236.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMRX | KROS |
|---|---|---|
| Share price | $3.94 | $11.95 |
| Market cap | $254.91M | $236.93M |
| 1-day change | +5.35% | +2.66% |
| YTD return | -40.12% | -41.31% |
| 1-year return | -36.86% | -25.87% |
| 5-year return | -84.15% | -69.35% |
| EPS (TTM) | $-0.98 | $-3.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.48 | $22.55 |
| 52-week low | $3.60 | $9.69 |
| Distance from 52-week high | -53.54% | -47.01% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +335.79% | +65.94% |
| Average volume | 708.12K | 194.05K |
| Shares outstanding | 64.70M | 19.83M |
| Employees | 57 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KROS has outperformed IMRX by 11.0 percentage points over the past year.
About Immuneering
IMRX stock →Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
IMRX vs KROS FAQ
Which is bigger, Immuneering or Keros Therapeutics?
Immuneering (IMRX) is larger, with a market capitalization of $254.91M compared with $236.93M for Keros Therapeutics (KROS).
Which stock has performed better over the past year, IMRX or KROS?
KROS returned -25.87% over the past 12 months, compared with -36.86% for IMRX (price return, excluding dividends). Past performance does not predict future results.
Are Immuneering and Keros Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.